XML 44 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Settlement and Payments (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Apr. 05, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Aug. 10, 2012
Common stock purchase options       327,150 739,000    
Stock option exercisable date Apr. 05, 2023            
Common stock closing price, per share $ 1.12           $ 18.2000
Stock options valuation amount $ 1.081            
Loss on extinguishment of debt   $ (116,407)    
Common stock options issued $ 135,125            
Accounts payable paid 124,025            
Total stockholders'’ deficiency   $ 5,359,154   $ 5,359,154   $ 4,355,384  
Accrued Liability [Member]              
Loss on extinguishment of debt 54            
Accounts Payable [Member]              
Loss on extinguishment of debt $ 11,100            
Valuation Technique, Option Pricing Model [Member] | Volatility [Member]              
Fair value assumptions, measurement input, percentages 18607.00%            
Valuation Technique, Option Pricing Model [Member] | Risk-Free Rate [Member]              
Fair value assumptions, measurement input, percentages 2.64%            
Valuation Technique, Option Pricing Model [Member] | Expected Dividend Rate [Member]              
Fair value assumptions, measurement input, percentages 0.00%            
Valuation Technique, Option Pricing Model [Member] | Expected Term [Member]              
Fair value assumptions, measurement input, term 5 years            
Robert N. Weingarten [Member]              
Common stock purchase options 185,388            
Accrued compensation $ 200,350            
Value of options granted $ 200,404            
Pharmaland Executive Consulting Services LLC [Member]              
Common stock purchase options 125,000